Payment overview · 2025
General Payments
$1,078.37
50 reported records · 19 companies
Healthcare provider profile · identity verified
Rupal R Desai, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ELLICOTT CITY, MD · NPI 1376634626
Verified facts
What the public records show
CMS Open Payments records show Rupal R Desai, M.D. received $1,078.37 in general payments during 2025 across 50 reported records.
PFIZER INC. accounted for 15.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $166.29 | 15.4% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $156.63 | 14.5% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $121.12 | 11.2% | 7 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $91.52 | 8.5% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $73.32 | 6.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.27 | 5.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $58.68 | 5.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.31 | 4.5% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.12 | 4.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $42.77 | 4.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $41.04 | 3.8% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $27.46 | 2.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $26.01 | 2.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.94 | 2.3% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $24.88 | 2.3% | 1 | 2025 |
| AERIN MEDICAL INC. | Unresolved — no canonical attribution shown | $22.97 | 2.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.69 | 1.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.76 | 1.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$13.59 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,078.37 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $126.57 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $93.62 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $91.52 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $73.32 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $73.32 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $65.50 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $61.41 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $49.91 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.35 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $44.12 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $42.77 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $41.04 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $39.72 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $39.72 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.72 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $39.29 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $39.29 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.77 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.65 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.65 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $27.46 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $27.46 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $26.01 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| RHINAER STYLUS Normalized: rhinaer stylus |
Device | AERIN MEDICAL INC. | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| VIVAER STYLUS Normalized: vivaer stylus |
Device | AERIN MEDICAL INC. | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.71 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 312 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 263 | 76 |
| Atorvastatin Calcium | Atorvastatin Calcium | 239 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 195 | 62 |
| Losartan Potassium | Losartan Potassium | 171 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 154 | 40 |
| Metformin Hcl | Metformin Hcl | 112 | 33 |
| Carvedilol | Carvedilol | 110 | 30 |
| Omeprazole | Omeprazole | 101 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 22 |
| Lisinopril | Lisinopril | 92 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 27 |
| Alendronate Sodium | Alendronate Sodium | 85 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 80 | 18 |
| Montelukast Sodium | Montelukast Sodium | 70 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 26 |
| Azelastine Hcl | Azelastine Hcl | 67 | 29 |
| Simvastatin | Simvastatin | 61 | 20 |
| Metformin Hcl Er | Metformin Hcl | 59 | 21 |
| Sertraline Hcl | Sertraline Hcl | 56 | 17 |
| Gabapentin | Gabapentin | 55 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 16 |
| Glipizide Er | Glipizide | 50 | 15 |
| Famotidine | Famotidine | 49 | 17 |
| Trazodone Hcl | Trazodone Hcl | 47 | 16 |
| Synthroid | Levothyroxine Sodium | 45 | 12 |
| Estradiol | Estradiol | 44 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 41 | 13 |
| Allopurinol | Allopurinol | 40 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 11 |
| Meloxicam | Meloxicam | 36 | 22 |
| Atenolol | Atenolol | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | 11 |
| Valsartan | Valsartan | 28 | suppressed |
| Furosemide | Furosemide | 27 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 21 |
| Lorazepam | Lorazepam | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 15 |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 22 | 16 |
| Armour Thyroid | Thyroid,pork | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 18 |
| Azithromycin | Azithromycin | 21 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 21 |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,078.37 · 50 records | PFIZER INC. | ABRYSVO, AREXVY, CAPLYTA, CAPVAXIVE, COMIRNATY, CREON, EVENITY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, GVOKE HYPOPEN, INTELLIS ADAPTIVESTIM, JARDIANCE, KISUNLA, Kerendia, LEQVIO, MOUNJARO, NP Thyroid 60, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, REPATHA, RHINAER STYLUS, Rybelsus, SHINGRIX, UBRELVY, VIVAER STYLUS, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error